Science · 3 views
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
There's new hope for the millions of people affected by chronic hepatitis B (CHB), a liver condition that can lead to cancer, scarring, or organ failure, and which is responsible for over a million deaths worldwide each year.
AI Summary
The FDA has approved bepirovirsen, marketed as Hibsago, for the treatment of chronic hepatitis B (CHB). The decision follows positive results from two phase 3 clinical trials that were published in the New England Journal of Medicine. CHB affects millions worldwide and can progress to liver cancer, scarring or organ failure, contributing to more than a million deaths each year. The approval offers the first therapy described as a “functional cure” for the disease.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Science
Continue reading recent Science coverage
- Centuries-old cemetery helps scientists link climate shocks to Industrial Revolution diseaseContinue reading
- Why so many British pubs are closing downContinue reading
- A Quantum Computer Could Crack Major Internet Encryption in Just 3 Days, Study SuggestsContinue reading
- European orbiter detects fresh hints of volcanic activity on MarsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow